Combination Chemotherapy for Advanced Small Bowel Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) for people with advanced small bowel adenocarcinoma that cannot be surgically removed. It is for those who have not yet had treatment for their advanced cancer, except possibly one cycle of FOLFOX.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of small bowel cancer called adenocarcinoma that has spread and cannot be surgically removed.
- Your tumor is mismatch repair proficient (MMRp) or microsatellite stable (MSS).
- You have not had prior treatment for advanced disease (except possibly one cycle of FOLFOX).
- You are generally active (ECOG 0 or 1) and have adequate organ function as checked by blood tests and heart rhythm.
- You are 18 years or older and willing to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two standard chemotherapy combinations (FOLFIRINOX and FOLFOX) in people with small bowel adenocarcinoma that cannot be removed by surgery or has spread. It aims to see which works better for people who haven't had chemotherapy before.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial tests a combination of four chemotherapy drugs (NALIRIFOX) as a first treatment for people with advanced appendix or small intestine cancer. It aims to see if this combination is safe and effective.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
Hear when a new Small Bowel Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.